Table 3 Treatment-related adverse events
Adverse event | Pyrotinib (n = 78), n (%) | |||
|---|---|---|---|---|
All Grades | Grade 1 | Grade 2 | Grade 3 | |
Any | 71 (91.0) | 70 (89.7) | 45 (57.7) | 16 (20.5) |
Occurring in ≥ 10% of patients |  |  |  | |
Diarrhea | 67 (85.9) | 25 (32.1) | 29 (37.2) | 13 (16.7) |
Fatigue | 45 (57.7) | 39 (50.0) | 5 (6.4) | 1 (1.3) |
Anemia | 28 (35.9) | 18 (23.1) | 8 (10.3) | 2 (2.6) |
Dizziness | 26 (33.3) | 25 (32.1) | 1 (1.3) | Â |
Decreased appetite | 25 (32.1) | 22 (28.2) | 3 (3.8) | Â |
Hand-foot syndrome | 25 (32.1) | 22 (28.2) | 3 (3.8) | Â |
Nausea | 25 (32.1) | 24 (30.8) | 1 (1.3) | Â |
WBC decreased | 19 (24.4) | 13 (16.7) | 6 (7.7) | Â |
Blood creatinine increased | 19 (24.4) | 19 (24.4) | Â | Â |
Cough | 18 (23.1) | 18 (23.1) | Â | Â |
ALT increased | 17 (21.8) | 17 (21.8) | Â | Â |
Vomiting | 16 (20.5) | 13 (16.7) | 3 (3.8) | Â |
Headache | 16 (20.5) | 16 (20.5) | Â | Â |
AST increased | 15 (19.2) | 15 (19.2) | Â | Â |
Hypokalemia | 14 (17.9) | 14 (17.9) | Â | Â |
Weight decreased | 12 (15.4) | 11 (14.1) | 1 (1.3) | Â |
Pain | 12 (15.4) | 12 (15.4) | Â | Â |
Hyponatremia | 11 (14.1) | 11 (14.1) | Â | Â |
Chest distress | 10 (12.8) | 9 (11.5) | 1 (1.3) | Â |